NRF2-driven thiol metabolism creates a selective vulnerability to selenite
Ting Chao, Yun Huang, Niklas B Thompson, Jing-Chun Lin, Ryan Martin, Rithwik Paladugu, Yi-Han TangiD, Svitlana Altukhova, Shayla Pham, Basma A Yasseen, Feroza K Choudhury, Archi Patel, Min Liu, Bin FangiD, John Koomen, Jose Serrano-Velez, W. Gregory Sawyer, Hardik Shah, Mingxiang TengiD, Chang JiangiD
Abstract
NRF2 hyperactivation caused by mutations in KEAP1 or NFE2L2 occurs in 20-30% of non-small cell lung cancers and confers therapy resistance. Here we show that NRF2-driven metabolic reprogramming creates a selective vulnerability to selenite. NRF2-dependent thiol export promotes the extracellular reduction of selenite to selenide. Our data support a model in which selenide enters cells and reaches mitochondria, where sulfide-quinone oxidoreductase uses selenide and glutathione to generate the selenopersulfide GS-SeH. A four-hour pulse of selenite was sufficient to induce cell death after washout, consistent with a selenium redox cycle that consumes NADPH and regenerates selenide. Within hours, selenite abolished aconitase activity and impaired mitochondrial respiration. The resulting cell death occurred independently of apoptosis, ferroptosis, pyroptosis, necroptosis and disulfidptosis. In mice, a selenite-rich diet selectively suppressed the growth of NRF2-hyperactive tumors. These findings identify an NRF2-driven metabolic vulnerability and support further investigation of selenite as a therapeutic strategy for NRF2-hyperactive cancers.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- NRF2 activation induces NADH-reductive stress providing a metabolic vulnerability in lung cancer
Tommy Weiss‐Sadan, Maolin Ge, … Liron Bar‐Peled·Cell MetabolismPeer-reviewed·Feb 24, 2023
- Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer
Y. P. Kang, L. Torrente, … G. M. DeNicola·bioRxiv·Nov 1, 2018
- Small Molecule Screen Identifies Pyrimethamine as an Inhibitor of NRF2-driven Esophageal Hyperplasia
C. Paiboonrungruang, Z. Xiong, … X. Chen·Redox BiologyPeer-reviewed·Nov 1, 2023
- A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer
C. Jiang, N. P. Ward, … G. M. DeNicola·bioRxiv·Mar 8, 2022
- Pyrimethamine inhibits mutant NRF2 as a molecular glue
Zhaohui Xiong, Chorlada Paiboonrungruang, … Xiaoxin Luke Chen·bioRxiv·Aug 18, 2025
- Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone
L. Torrente, N. Prieto, … G. M. DeNicola·bioRxiv·Nov 25, 2019